The CKD-related GH insensitivity is characterized by deficiency of functional IGF-1, and can be overcome by the administration of supraphysiological doses of recombinant human GH (rhGH); long-term rhGH treatment stimulates IGF1 synthesis, increases longitudinal growth and likely improves adult height (216). The gene discussed is IGF1; the disease is chronic kidney disease.